Madrigal Pharmaceuticals
Matt Dauphin currently serves as the Executive Director of Clinical Operations & Project Management at Madrigal Pharmaceuticals since January 2020. Previously, Matt held the position of Director of Clinical Pharmacology & Product Development at HighTide Therapeutics, managing global Phase 1-3 clinical development programs with a focus on hepatology. Prior experience includes roles at Incyte Corporation as Associate Director of Clinical Pharmacology, where operational standardization of clinical studies was a key responsibility, and at Shire Development LLC as Associate Director, overseeing multiple clinical development programs across various therapeutic areas. Matt began their career as a Sr. Project Coordinator at Cato Research Ltd., contributing to pre-clinical and clinical study services. Educational qualifications include a Master's degree in Biotechnology from The Johns Hopkins University and a Bachelor's degree in Biology from McDaniel College.
Madrigal Pharmaceuticals
4 followers
Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company pursuing novel therapeutics that target a specific thyroid hormone receptor pathway in the liver, which is a key regulatory mechanism common to a spectrum of cardio-metabolic and fatty liver diseases with high unmet medical need.